Awarded
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Omalizumab, ATC R03DX05 für die Zeit 01.08.2024 - 31.07.2025 (zzgl. Verlängerungsoption 1x12 Monate)
Original language: German
Track this recordWith Adjudera Pro, get alerted before a contract here runs out.
- Buyer
- DAK-Gesundheit
- Winners
- Abacus Medicine A/S, ACA Müller ADAG Pharma AG, Allomedic GmbH, axicorp Pharma B.V., axicorp Pharma GmbH, CC Pharma GmbH, Celltrion Healthcare Deutschland GmbH, EurimPharm Arzneimittel GmbH, kohlpharma GmbH, Novartis Pharma GmbH, Orifarm GmbH, Originalis B.V., Paranova Pack A/S
- Contract value
- no value published
- Bids received
- 9
- Published
- 1 Sept 2026
- Awarded
- 1 Aug 2024
- Contract start
- 1 Aug 2024
- Contract end
- 14 Aug 2025estimated
- Region
- Hamburg